Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Advances Candidates, Brings In Phase II Molecules To Quell Pipeline Worries

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

It was all about the pipeline during Eli Lilly’s fourth quarter earnings call, as company execs strove to convince analysts they’ve made progress in efforts to counter revenue losses from big-ticket products about to lose patent protection.

You may also be interested in...

FDA's Victoza Decision BalancedUnknown Cancer Risk Against Known FDAAA Measures

FDA’s approval of Novo Nordisk’s type 2 diabetes drug Victoza (liraglutide) was a bit surprising for an agency often seen as increasingly conservative, even given that the Jan. 25 decision came with extensive labeling, risk management and mandatory post-market studies focused on the cancer risk.

BMS, Lilly Reach Agreement To Co-Develop Erbitux Follow-On

During its fourth-quarter 2009 earnings call, Bristol also urged investors to show patience with disappointing sales of Onglyza.

FDA Clears Victoza, But Warnings And More Studies Pose Hurdles

Liraglutide's US approval comes with a black box warning for a thyroid cancer risk and hefty post-marketing requirements.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts